Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomised, controlled trial
Journal of the European Academy of Dermatology and Venereology | Oct 21, 2020
Most read this week